Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Bioligent

Clinicaltrial registered26 Oct 2026

Bioligent

26 Oct 2026: Trial registered · A Clinical Trial to Evaluate the Effects of Adrenal Adapt on Sleep Quality, Daytime Energy, Stress Resilience, and Cognitive Performance.. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
26 Oct 2026
Title
A Clinical Trial to Evaluate the Effects of Adrenal Adapt on Sleep Quality, Daytime Energy, Stress Resilience, and Cognitive Performance.
Conditions
Improves Daytime Energy Levels, Reduces Afternoon Energy Crashes and Midday Fatigue, Improves Overall Sleep Quality and Restorative Sleep, Helps People Fall Asleep Faster and Wake Less During the Night
Phase
Not applicable
Study Type
Interventional
Status
Recruiting
Countries
United States
Country
United States
Reference
NCT07893561
Location
United States
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Bioligent

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from United States

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.